Market revenue in 2023 | USD 47.8 million |
Market revenue in 2030 | USD 105.4 million |
Growth rate | 11.9% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.98% in 2023. Horizon Databook has segmented the Argentina immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Supportive government initiatives, such as funding & awareness programs, and extensive R&D activities directed toward the development of novel biomarkers are factors expected to boost the Argentina biomarkers market growth.
Furthermore, an increase in the prevalence of Alzheimer’s disease is anticipated to drive the market. For instance, according to the Alzheimer’s Association of Argentina, Alzheimer’s disease affects more than 300,000 people and is the fifth leading cause of death in Argentina.
Usage of outdated technology is limiting the number of cases being diagnosed, which leads to a large number of cases being underdiagnosed. However, the launch of new early neurodegenerative disease diagnosis programs by various institutes, such as the Alzheimer’s Association, is expected to propel the demand for novel diagnostics and prognostic tools, such as biomarkers, in the coming years.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Argentina immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account